Precision lifestyle program for Emiratis with obesity in Abu Dhabi

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective interventional study will enroll 150 Emirati adults aged 25-50 with BMI 30-35 kg/m² in Abu Dhabi. Participants will receive a precision lifestyle medicine program tailored to their health profile, and outcomes will be compared to 150 propensity-matched individuals receiving standard IFHAS care. The trial uses IFHAS screening data to identify risk profiles and guide personalized interventions over an 18-week period. Primary endpoints center on changes in cardiometabolic biomarkers, with secondary analyses exploring associations between lifestyle factors and chronic disease risk. Recruitment is rolling, with specific inclusion and exclusion criteria to ensure suitability for exercise and imaging components.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Emiratis residing in Abu Dhabi emirate
* Aged 25-50 years
* BMI 30-35 kg/m²
* Thiqa cardholder
* Previous participation in IFHAS screening
* Able to provide informed consent
* Participant in the Emirati Genome Programme
* No weight-loss medications (e.g., Ozempic, Saxenda, Wegovy) within 3 months of enrollment.

Exclusion Criteria:

* Aged under 25 years or over 50 years of age
* BMI range under 30 kg/m2 and over 35 kg/m2
* Taking weight loss medication such as GLP-1 drugs (Ozempic, Saxenda, Wegovy)
* Active treatment for serious medical conditions (cancer, planned surgery, immunomodulation)
* Transplant surgery within 12 months
* Pregnancy
* Surgery within 3 months prior to recruitment
* Physical limitations preventing exercise participation
* Current enrolment in other lifestyle intervention programs
* Active psychiatric conditions, cognitive impairment, or mental health conditions affecting study participation
* Contraindication to MRI or DEXA imaging, including severe claustrophobia or need for sedation.

Where it's running

• Institute for Healthier Living
  Abu Dhabi, United Arab Emirates Recruiting

Study contacts

• Principal investigator: Nicole Sirotin, MD — Institute for Healthier Living Abu Dhabi
• Study coordinator: Erik Koornneef, PhD
• Email: e.koornneef@ihlad.ae
• Phone: +971500888594

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VK3019 in overweight and obese adults without other health conditions

  This early-phase study tests VK3019 vs placebo to see if it is safe and how it behaves in the body in overweight and obese adults who don’t have other medical conditions.

  Recruiting Phase 1 Viking Therapeutics, Inc. · Lake Forest, California · NCT07846033

• VK2735 in Obese Adults: A First-in-Humans Dose Rocusing Safety and PK/PD

  This Phase 1 study tests VK2735 versus placebo to see if it is safe and tolerable in obese adults (BMI ≥ 30) without other diseases.

  Recruiting at 2 sites Phase 1 Viking Therapeutics, Inc. · Lake Forest, California and 1 other locations · NCT07838740

• Natural history and prognostic factors of therapeutic response in sub-phenotypes of obesity

  This study follows adults with obesity or overweight to see how different subtypes respond to obesity therapies using data and machine learning.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bologna · NCT07666425

• Omega‑3 (EPA) for depression linked to inflammation in adults with obesity

  This trial tests whether taking 2 g/day of EPA omega‑3 for 12 weeks helps reduce depressive symptoms in antidepressant‑free adults with obesity who have low omega‑3 levels.

  Recruiting National Science and Technology Council, Taiwan · Taichung, Taichung · NCT07439744

• Postpartum Cardiovascular Care After Pregnancy

  This study tests whether a postpartum education program can improve blood pressure and early heart‑health markers in women in their third trimester to six months after giving birth in Accra, Ghana.

  Recruiting University of North Carolina, Greensboro · Accra · NCT07420465

• MB-1 vs placebo for weight and metabolic health in adults who are overweight or obese

  A study will test MB-1 to see if it helps adults who are overweight or obese lose weight and improve metabolic health compared to a placebo.

  Recruiting Arrae · London, Ontario · NCT07363148

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.